… HPV vaccine. In an effectiveness study covering the entire Swedish population, HPV vaccine
effectiveness against genital warts … <14 years) and vaccine effectiveness decreased with …

… HPV vaccine, the question now is whether the vaccine is in fact … Gardasil ® the question of
which clinical endpoint should be monitored, was addressed. Clearly the most significant HPV-…

… quadrivalent HPV vaccine were effective against genital warts in our population. Moreover,
with low vaccine coverage the incidence of genital warts decreased only in the vaccinated. …

… Types 6 and 11 do not contribute to the incidence of high-grade dysplasias (precancerous
lesions) or cervical cancer, but do cause laryngeal papillomas and most genital warts. …

… To assess the effectiveness of the HPV vaccines in preventing genital warts (GW) in women
aged 14–23 years and to estimate the incidence of GW in the whole population aged from …

… Genital warts caused by HPV 6 and 11 have a lifetime risk of acquisition of 10%. HPV vaccines
are subunit vaccines … Two vaccines have been licenced since 2006/2007 and are in the …

… human papillomavirus (HPV) vaccine has been assumed to give protection against genital
warts (GW) as well as cervical cancer. Our main question was whether HPV vaccine has any …

… time after vaccine programs have been implemented. Since the impact of HPV vaccination
on … genital warts reduction in countries with HPV vaccination programs including quadrivalent …

… HPV 6 and 11 cause 85% of all genital warts and some low-grade lesions at various sites. …
HPV vaccine and later in the nonavalent vaccine. Once more than one HPV vaccine was …

… of HPV vaccine in preventing the relapse of ano-genital warts. The results suggest that HPV
vaccination does not provide secondary benefit in patients with previous ano-genital warts. …